Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.36 |
| ▸ | BRAF | P15056 | 8/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473226 | 0.86 | KDR (0.38) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4470750 | 0.82 | KDR (0.37) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4459588 | 0.77 | KDR (0.44) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4473222 | 0.77 | KDR (0.44) | KDRRAF1 | |
| SCHEMBL4485733 | 0.75 | RET (0.42) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4470287 | 0.74 | KDR (0.50) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4463488 | 0.72 | KDR (0.50) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4463607 | 0.72 | BRAF (0.41) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4470743 | 0.72 | KDR (0.45) | KDRBRAFRAF1HIPK4RET | |
| SCHEMBL4480053 | 0.71 | RET (0.57) | KDRBRAFRAF1HIPK4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685125-B1 | Pyrrole derivatives useful for the treatment of proliferative diseases | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-7598274-B2 | N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | claimed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| US-7598274-B2 | N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149594-A1 | Pyrrole derivatives | RAF1, BRAF, ARAF | KDR 2076/4885BRAF 2/4885RAF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.